Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial

Lorusso, Domenica; Xiang, Yang; Hasegawa, Kosei; Scambia, Giovanni; Leiva, Manuel; Ramos-Elias, Pier; Acevedo, Alejandro; Sukhin, Vladyslav; Cloven, Noelle; Gomes, Andrea J. Pereira de Santana; Mejia, Fernando Contreras; Reiss, Ari; Ayhan, Ali; Lee, Jung-Yun; Saevets, Valeriya; Zagouri, Flora; Gilbert, Lucy; Sehouli, Jalid; Tharavichitkul, Ekkasit; Lindemann, Kristina; Lazzari, Roberta; Chang, Chih-Long; Lampe, Rudolf; Zhu, Hong; Oaknin, Ana; Christiaens, Melissa; Polterauer, Stephan; Usami, Tomoka; Li, Kan; Yamada, Karin; Toker, Sarper; Keefe, Stephen M.; Pignata, Sandro; Duska, Linda R.

doi:10.1097/OGX.0000000000001317

YUHSpace

BROWSE

0 188

Cited 0 times in

Cited 1 times in

Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial

Authors: Lorusso, Domenica ; Xiang, Yang ; Hasegawa, Kosei ; Scambia, Giovanni ; Leiva, Manuel ; Ramos-Elias, Pier ; Acevedo, Alejandro ; Sukhin, Vladyslav ; Cloven, Noelle ; Gomes, Andrea J. Pereira de Santana ; Mejia, Fernando Contreras ; Reiss, Ari ; Ayhan, Ali ; Lee, Jung-Yun ; Saevets, Valeriya ; Zagouri, Flora ; Gilbert, Lucy ; Sehouli, Jalid ; Tharavichitkul, Ekkasit ; Lindemann, Kristina ; Lazzari, Roberta ; Chang, Chih-Long ; Lampe, Rudolf ; Zhu, Hong ; Oaknin, Ana ; Christiaens, Melissa ; Polterauer, Stephan ; Usami, Tomoka ; Li, Kan ; Yamada, Karin ; Toker, Sarper ; Keefe, Stephen M. ; Pignata, Sandro ; Duska, Linda R.

Citation: OBSTETRICAL & GYNECOLOGICAL SURVEY, Vol.79(9) : 523-524, 2024-09

Journal Title: OBSTETRICAL & GYNECOLOGICAL SURVEY

ISSN: 0029-7828

Issue Date: 2024-09

Abstract: (Abstracted from Lancet 2024;403:1341-1350) Prognosis for locally advanced cervical cancer is poor, with 5-year progression-free survival (PFS) and overall survival ranging from 47% to 80%. For the past several decades, treatment has included external beam radiotherapy with concurrent chemotherapy followed by brachytherapy, and novel therapeutic options are needed.

DOI: 10.1097/OGX.0000000000001317

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers

Yonsei Authors: Lee, Jung-Yun(이정윤) https://orcid.org/0000-0001-7948-1350

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/202302

사서에게 알리기

Show full item record Find it @ YMLIB

License

YUHSpace: Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial

YUHSpace

BROWSE

Browse

Links